查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837246

按治療類型、給藥途徑、藥物類別、適應症和最終用戶血栓症藥物市場—2025-2032年全球預測

Thrombosis Drug Market by Treatment Type, Route Of Administration, Drug Class, Indication, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血栓症治療市場規模將達到 488.4 億美元，複合年成長率為 6.01%。

關鍵市場統計數據
基準年2024年 306億美元
預計年份：2025年 324.8億美元
預測年份 2032 488.4億美元
複合年成長率 (%) 6.01%

本文簡要介紹了治療方法進展、臨床醫生偏好和政策轉變如何重新定義血栓症治療服務和商業性優先事項。

在新的藥物選擇、不斷發展的診療路徑以及患者對以患者為中心的治療效果日益成長的期望的推動下，血栓症治療已進入持續的臨床和商業性轉型階段。近年來，直介面服抗凝血劑已成為許多適應症的主要治療手段，而注射劑在急性期和手術全期治療中發揮關鍵作用。同時，臨床醫生和醫療系統必須權衡療效和安全性、監測負擔以及門診病人管理的物流需求。這些動態共同影響醫院的執業資格、門診診療通訊協定以及健保報銷政策。

臨床醫師越來越傾向選擇藥物動力學可預測、監測需求低、逆轉策略明確的療法。這些偏好正在推動處方行為的改變，並重塑處方決策。同時，從外科患者的預防性治療到心房顫動和靜脈血栓栓塞症的長期管理，血栓症治療都需要根據具體適應症採取細緻入微的策略，充分考慮患者的合併症、伴隨用藥以及依從性問題。轉化科學，包括基於生物標記的風險分層和精準給藥，正逐步為更具針對性的治療方法選擇提供依據。

法律規範和支付方正積極應對這些臨床現實，更加重視真實世界證據和療效比較數據，並傾向於整合可靠的療效數據、患者支持服務和臨床醫生教育的產品策略。本報告的以下章節將探討最重要的變化、不斷變化的貿易和海關環境的影響、治療和給藥途徑細分、區域格局、競爭動態、對行業領導者的建議以及檢驗的調查方法。

臨床便利性、真實世界價值體現、供應鏈韌性以及逆轉策略如何重塑血栓症治療的格局

血栓症治療領域正經歷變革性的轉變，涵蓋治療創新、醫療服務模式和商業策略等各個面向。其中一個根本性的轉變是從密集監測模式轉向簡化門診管理的治療方法。口服抗凝血劑的廣泛應用正是這種轉變的體現，它減少了頻繁的實驗室監測需求，從而促進了以地區為基礎醫療服務的擴展，減輕了診所的負擔。同時，數位健康工具和遠端監測平台也被納入長期抗凝血治療管理，有助於提高患者依從性並及早發現不利事件。

另一個重要的轉變是逆轉策略和輔助性治療的成熟。隨著臨床醫師對出血風險管理的信心增強，處方模式也隨之改變，傾向於選擇具有明確逆轉作用且有完善的緊急抗凝血逆轉通訊協定的藥物。與臨床研發同步，生產商正在調整其商業性策略，強調透過真實世界證據和支付方參與的結局研究來證明其價值。這些努力旨在透過證明住院率、再入院率和出血相關併發症的減少，來解決報銷障礙，並調整定價和合約條款。

供應鏈韌性和生產策略如今也正在塑造競爭格​​局。各公司正在最佳化生產佈局並建立策略夥伴關係。這些因素共同作用，打造了一個以病人為中心、數據主導且商業性化程度更高的市場。

評估近期關稅政策變化和貿易政策調整如何影響血栓症藥物的供應鏈策略、採購決策和成本動態。

關稅措施和貿易政策調整血栓症藥物的累積影響，正為生產商、經銷商和醫療保健系統帶來新的商業性挑戰。進口關稅和貿易壁壘的增加可能會推高成品藥、原料藥以及口服和注射劑型專用包裝的成本。這些成本壓力可能會波及與醫院和零售藥局的採購談判，改變定價策略，並促使關鍵生產環節在國內或近岸地區轉移，以規避跨境關稅風險。

如果生產轉移到其他司法管轄區，在考慮關稅因素的情況下重組供應鏈通常會導致產品資格確認和監管核准的前置作業時間延長。對於同時擁有口服直接抗凝血劑和注射用肝素類藥物的製造商而言，他們必須權衡生產轉移與接受進口成本波動之間的監管和物流利弊。此外，關稅也會影響二級包裝和分銷中心的選址決策，進而影響庫存緩衝和區域對需求激增的應對力。

從支付方和醫療服務提供方的角度來看，成本不確定性的增加將促使雙方制定更嚴格的契約，提高對成本抵消證據的需求，並更加關注對醫療總成本的影響。醫療系統可能更傾向於選擇採購管道可預測、供應商網路多元化的治療方案。為此，領先的製造商正在加速推進策略性舉措，以降低關稅風險，包括供應商多元化、簽訂長期供應協議以及進行選擇性的本地生產投資，從而保障醫療服務的連續性，並在關鍵市場保持競爭力。

透過整合治療類型、給藥途徑、藥物類別、適應症和最終用戶等因素進行細分，可以揭示最佳化的臨床定位和商業化路徑。

細分市場分析揭示了不同治療類型、給藥途徑、藥物類別、適應症和最終用戶之間存在的臨床和商業動態差異，從而為制定量身定做的產品和市場策略提供了基礎。根據治療類型，需要預防的患者和需要積極治療的患者被歸類在不同的治療路徑。預防包括針對高風險住院病患的藥物預防和針對圍手術手術全期管理的外科預防，而治療則包括溶栓治療等急性治療以及針對二級預防和慢性風險管理的長期治療。每種治療路徑對起效時間、監測和病患教育都有其獨特的要求。

從給藥途徑來看，注射劑和口服藥物之間存在著策略性的差異。注射療法，即靜脈注射或皮下注射，在需要快速起效和劑量調整的場合至關重要，例如急診醫院、急診醫學和手術全期方案。口服藥物，以膠囊或片劑形式提供，是長期門診病人治療的主要手段，特別適用於藥物動力學可預測且給藥方案便捷的藥物，以提高患者的依從性。給藥途徑的差異會影響物​​流、病患體驗和臨床經濟效益。

藥物分類展現出清晰的競爭格局和臨床應用上的細微差別。抗血小板藥物、直介面服抗凝血劑、低分子肝素、未分級肝素和維生素K拮抗劑各自針對特定適應症發揮不同的作用。直介面服抗凝血劑可進一步分為直接凝血酶抑制劑和Xa因子抑制劑，其中Xa因子抑制劑包括Apixaban班、貝曲沙班、艾多沙班和利伐沙班。低分子肝素包括達肝素、依諾肝素和亭扎肝素。當成本、監測基礎設施或存在其他藥物的特異性禁忌症成為考慮因素時，維生素K拮抗劑（例如Warfarin）仍然佔據著一定的市場地位。這些差異會影響處方決策、臨床指南和患者諮詢。

按適應症（例如心房顫動、深層靜脈栓塞症和肺動脈栓塞）進行細分，有助於產品定位和價值溝通，因為不同疾病的治療目標和可接受的風險程度各不相同。按終端用戶（包括醫院和零售藥局）細分，可以進一步明確分銷模式和合約機制。醫院專注於急性期護理準備和注射劑的庫存管理，而零售藥局則優先考慮依從性計劃和門診口服藥物的取得。了解這些人口統計數據有助於製造商最佳化通訊、改善管道策略，並使實證醫學的研發更符合臨床醫生和支付方的特定需求。

美洲、歐洲、中東和非洲以及亞太地區的臨床實踐、報銷框架和供應鏈現狀將如何決定差異化的商業化策略？

區域動態正在影響三大全球叢集（美洲、歐洲、中東和非洲以及亞太地區）的臨床實踐、監管預期和商業性策略。在美洲，臨床應用趨勢強調口服抗凝血劑的更廣泛接受度以及對門診管理基礎設施的日益重視。市場准入討論通常取決於治療方法對總醫療成本以及住院率和再入院率的影響。

由於監管路徑和醫療保健資金籌措模式的差異，中東和非洲地區的技術採納時間呈現不均衡的局面。在該地區的許多市場，比較療效和衛生技術評估證據都受到重視，這使得直接比較結果和衛生經濟模型的重要性日益凸顯。當地的臨床指南、報銷標準和採購框架可能存在顯著差異，因此製造商需要製定量身定做的打入市場策略並產生針對特定區域的證據。

在亞太地區，資源匱乏地區仍依賴注射療法和維生素K拮抗劑，而都市區三級醫院則正迅速採用新型藥物。供應鏈在地化和定價在亞太地區尤其重要，影響生產夥伴關係和分級定價策略的決策。在整個亞太地區，人口結構變化、人口老化以及心房顫動和靜脈血栓栓塞症盛行率的上升，都促使企業需要製定適應性強的商業性策略，以應對當地的支付方結構、患者支付能力和分銷管道的複雜性。

在整個血栓症治療生態系統中，透過具有競爭力和策略性的企業行動，推動差異化、產品組合防禦和策略夥伴關係。

老牌製藥公司、新興專科藥物研發公司和非專利生產商之間的競爭動態將影響血栓症藥物的創新軌跡和市場推廣策略。擁有廣泛心血管產品組合的現有公司將利用其規模、已建立的臨床醫生關係和分銷網路來鞏固市場地位，並透過拓展適應症、聯合用藥策略和加強患者支援服務來延長產品生命週期。同時，靈活敏捷的專科藥物研發公司將專注於小眾適應症、新型作用機制和夥伴關係關係，以加速臨床開發和市場滲透。

在學名藥和生物相似藥領域，定價和市場准入壓力日益增大，尤其是像Warfarin和老一代肝素產品這樣的傳統藥物。在此環境下，原廠藥公司更有獎勵透過提供實證醫學證據、真實世界安全性數據以及整合服務來解決用藥依從性和監測方面的不足，從而實現差異化競爭。製藥公司與科技公司之間的策略聯盟日益普遍，將藥物療法與數位化依從性平台、遠端監測和臨床決策支援工具相結合，以改善治療效果並向支付方證明其價值。

併購和授權仍然是實現投資組合多元化和地理擴張的戰術性手段。在監管要求和採購慣例日益嚴格的環境下，能夠成功將臨床差異化、擴充性的生產製造和穩健的供應鏈相結合的公司將獲得競爭優勢。此外，對逆轉劑、快速診斷和特殊製劑的投資也能創造相關機遇，進而增強公司在急性和慢性照護領域的地位。

製造商可以採取哪些切實可行的策略步驟來加強其供應鏈，透過真實案例證明其價值，並針對醫院和零售通路調整商業化策略？

產業領導者現在即可採取行動，透過採取一系列切實可行、基於實證的策略來鞏固和提升自身地位，這些策略將臨床價值與商業性執行相結合：優先投資於產生可靠的真實世界證據，以解答支付方和臨床醫生關於療效比較、特殊人群安全性以及對醫療資源利用影響等方面的疑問。將這些數據舉措與有針對性的醫學推廣相結合，從而將證據轉化為臨床實踐和藥物目錄。

透過供應商多元化、投資關鍵零件的本地或近岸產能以及製定緊急庫存策略來增強供應鏈韌性，從而減輕關稅和貿易中斷的影響。這些營運措施將降低跨境成本壓力的風險，並確保我們口服和注射產品組合的持續供應。同時，設計差異化的患者援助計劃，以提高患者依從性，提供出血風險管理方面的教育，並促進患者在醫院和門診之間及時過渡。

採取針對不同管道的商業性策略，充分考慮醫院和零售藥局的不同需求，並據此調整合約、教育資源和分銷模式。與支付方合作，在適當情況下試點基於結果的契約，並考慮提供能夠顯著改善治療效果的附加價值服務，例如數位化依從性工具和打包式診療路徑。最後，維持嚴謹的產品線策略，平衡漸進式創新與顛覆性研究，探索新型機制和逆轉技術，以確保持續的臨床相關性和長期成長潛力。

一種綜合研究途徑，結合嚴謹的二手證據研究、相關人員訪談和三角綜合分析，以檢驗臨床和商業性見解。

本分析的調查方法結合了全面的二手文獻綜述、專家諮詢和結構化綜合分析，以確保其嚴謹性和有效性。二手文獻綜述包括對同儕審查的臨床文獻、監管指導文件、公開資訊和醫療服務利用調查的審查，旨在建立對臨床實踐模式、治療差異化和政策促進因素的基本理解。這些資料為評估臨床和商業性變數如何在不同治療層級和醫療環境中相互作用提供了事實基礎。

主要研究包括對臨床醫生、醫院藥劑師、支付方代表和行業高管進行深度訪談，以檢驗趨勢、探索決策促進因素並揭示實際應用中的障礙。對這些定性資料進行主題分析，使我們能夠確定相關人員最為關注的問題的優先順序。研究結果與專有的產品核可資料庫、藥物安全檢測摘要和已發表的衛生經濟模型進行交叉比對，以確保結果的一致性並識別策略意義。

本分析的限制包括：區域異質性可能導致招募時間和取得方法存在差異，快速發展的臨床數據可能導致研究期間以外的實踐模式發生變化。為減輕這些局限性，本研究強調交叉驗證、對新數據採取保守的解讀以及調查方法假設的透明化。我們鼓勵希望將本研究結果應用於特定領域的讀者申請情境分析或提取針對其特定地區或產品系列的補充資料。

本文概述了臨床發展、供應鏈調整和實證商業策略如何融合，共同塑造血栓症治療的未來。

摘要：在臨床創新、醫療服務模式轉變以及政策和供應鏈動態帶來的商業性壓力等因素的驅動下，血栓症藥物正經歷著意義深遠且持續的變革。口服抗凝血劑的興起以及注射劑在急診護理中持續的重要性，要求制定差異化的策略，充分考慮不同給藥途徑的物流、患者體驗以及床邊經濟效益。供應鏈的韌性以及基於證據的價值論證，如今對於確保藥物市場進入並在不同的醫療保健系統中持續應用至關重要。

成功的製造商會整合可靠的真實世界證據，投資於有針對性的數位化和患者支持解決方案，並調整生產策略以降低貿易相關風險。區域差異至關重要。針對當地報銷架構和臨床指引要求制定的市場推廣計劃，遠勝於千篇一律的模式。那些能夠平衡臨床差異化和卓越營運、積極與支付方和醫療服務提供者互動，並展現出可衡量的療效提升的機構，將獲得競爭優勢。

這些結論凸顯了及時採取行動的必要性。透過利用本分析中概述的策略性考量和營運建議，相關人員可以更好地應對不斷變化的臨床醫生偏好、監管審查和採購動態，從而改善患者照護和商業性績效。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 術後照護直介面服抗凝血劑迅速取代肝素
  • 透過基因生物標記分析增加對個人化血栓症治療的投資
  • 長效皮下注射凝血因子IX療法的出現降低了B型血友病患者的給藥頻率。
  • 擴大數位健康平台在遠端監測抗凝血治療依從性的應用
  • 生技新興企業公司與大型製藥公司進行策略合作，加速新型抗血栓藥物的研發
  • 隨著新型口服抗凝血劑（DOAC）患者族群的成長，對口服抗凝血劑逆轉劑的需求也增加。
  • 成本壓力下，生物類似抗凝血劑的監管核准途徑簡化
  • 擴大真實世界證據研究，以評估新型血栓症藥物的長期安全性和有效性

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按治療類型血栓症的血栓藥物市場

  • 預防
    • 醫療預防
    • 手術預防
  • 治療
    • 急性治療
    • 長期治療

第9章 依給藥途徑血栓症的血栓藥物市場

  • 注射
    • 靜脈
    • 皮下
  • 口服
    • 膠囊
    • 藥片

第10章血栓症藥物市場（依藥物類別分類）

  • 抗血小板藥物
  • 直介面服抗凝血劑
    • 直接凝血酶抑制劑
    • Xa因子抑制劑
      • Apixaban
      • 貝曲沙班
      • 艾多沙班
      • Rivaroxaban
  • 低分子量肝素
    • 達肝素
    • 依諾肝素
    • 欽扎帕林
  • 未分級肝素
  • 維生素K拮抗劑
    • Warfarin

第11章血栓症藥物市場（依適應症分類）

  • 心房顫動
  • 深層靜脈栓塞症
  • 肺動脈栓塞

第12章血栓症藥物市場（依最終用戶分類）

  • 醫院
  • 零售藥房

第13章血栓症藥物市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章血栓症藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國血栓症藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • Boehringer Ingelheim GmbH
    • Daiichi Sankyo Company, Limited
    • Leo Pharma A/S
    • Johnson & Johnson
    • Aspen Pharmacare Holdings Limited
    • GlaxoSmithKline plc
    • Amgen Inc.
    • Sanofi SA
Product Code: MRR-030298DFFFC8

The Thrombosis Drug Market is projected to grow by USD 48.84 billion at a CAGR of 6.01% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 30.60 billion
Estimated Year [2025] USD 32.48 billion
Forecast Year [2032] USD 48.84 billion
CAGR (%) 6.01%

A concise primer on how therapeutic advances, clinician preferences, and policy shifts are redefining thrombosis care delivery and commercial priorities

Thrombosis therapy has entered a phase of sustained clinical and commercial transformation driven by new pharmacologic options, evolving care pathways, and heightened expectations for patient-centered outcomes. Recent years have witnessed the consolidation of direct oral anticoagulants as a dominant therapeutic class for many indications, while injectable agents retain critical roles in acute and perioperative settings. Simultaneously, clinicians and health systems are balancing efficacy with safety, monitoring burden, and the logistical demands of outpatient management. These dynamics collectively influence hospital privileging, ambulatory care protocols, and payer reimbursement policies.

Clinicians increasingly prioritize treatments that offer predictable pharmacokinetics, reduced monitoring requirements, and clearly defined reversal strategies. This preference has catalyzed shifts in prescribing behavior and has reshaped formulary decision-making. At the same time, the spectrum of thrombosis care-from prevention in surgical patients to long-term management of atrial fibrillation and venous thromboembolism-requires nuanced, indication-specific approaches that consider patient comorbidity, concomitant medications, and adherence challenges. Translational science, including biomarker-driven risk stratification and precision dosing initiatives, is beginning to inform more tailored therapeutic choices.

Regulatory frameworks and payers are responding to these clinical realities by emphasizing real-world evidence and comparative effectiveness data. As a result, product strategies that integrate robust outcomes data, patient support services, and clinician education are gaining traction. In the sections that follow, this report examines the most consequential shifts, the implications of evolving trade and tariff environments, segmentation insights across treatment and administration routes, regional patterns, competitive dynamics, recommended actions for industry leaders, and methodological underpinnings of the research.

How clinical convenience, real-world value demonstration, supply chain resilience, and reversal strategies are collectively reshaping thrombosis treatment dynamics

The thrombosis treatment landscape is undergoing transformative shifts that span therapeutic innovation, care delivery models, and commercial strategy. One fundamental shift is the migration from intensive monitoring paradigms toward therapies that simplify outpatient management. This movement is reflected in broader adoption of oral anticoagulants that reduce the need for frequent laboratory monitoring, thereby enabling expanded community-based care and lower clinic burden. Complementing this, digital health tools and remote monitoring platforms are becoming embedded in long-term anticoagulation management, supporting adherence and early detection of adverse events.

Another pivotal change involves the maturation of reversal strategies and adjunctive therapies. As clinicians gain confidence in managing bleeding risks, prescribing patterns have evolved to favor agents with established reversal agents or managed protocols for urgent anticoagulation reversal. Parallel to clinical developments, manufacturers are restructuring commercial approaches to emphasize value demonstration through real-world evidence and payer-engaged outcomes studies. These efforts aim to address reimbursement hurdles and to align pricing and contracting with demonstrable reductions in hospitalization, readmission, or bleeding-related complications.

Supply chain resilience and manufacturing strategy also now shape competitive positioning. Companies are optimizing production footprints and forging strategic partnerships to ensure uninterrupted supply of both oral and injectable formulations. Lastly, the competitive landscape is intensifying with lifecycle management efforts, new molecular entities in development, and strategic alliances that accelerate market entry and broaden distribution channels. Together, these forces create a more patient-centric, data-driven, and commercially sophisticated market.

Assessing how recent tariff trends and trade policy shifts are influencing supply chain strategies, procurement decisions, and cost dynamics across thrombosis therapeutics

The cumulative impact of tariff actions and trade policy adjustments on thrombosis therapeutics has created a new layer of commercial complexity for manufacturers, distributors, and health systems. Increased import duties and trade barriers can elevate costs for finished drugs, active pharmaceutical ingredients, and specialized packaging used in both oral and injectable formulations. These cost pressures ripple through procurement negotiations with hospitals and retail pharmacies, alter pricing strategies, and may incentivize onshoring or nearshoring of critical manufacturing processes to manage exposure to cross-border tariffs.

Supply chain reconfiguration prompted by tariff considerations often results in longer lead times for product qualification and regulatory approval when production sites shift jurisdictions. Manufacturers managing portfolios that include both oral direct anticoagulants and parenteral heparin-based therapies must weigh the regulatory and logistical trade-offs of relocating production versus accepting variable import costs. Additionally, tariffs can influence decisions about where to locate secondary packaging and distribution hubs, affecting inventory buffers and local responsiveness to demand spikes.

From a payer and provider perspective, the added cost uncertainty encourages more stringent contracting, increased demand for cost-offset evidence, and closer scrutiny of total cost of care implications. Health systems may favor therapeutic options with predictable procurement channels and diversified supplier networks. In response, leading manufacturers are accelerating strategic initiatives to mitigate tariff exposure, including supplier diversification, long-term supply contracts, and selective local manufacturing investments to protect continuity of care and maintain competitive access in key markets.

Integrated segmentation intelligence across treatment type, administration route, drug class, indication, and end user illuminating optimized clinical positioning and commercialization pathways

Segmentation analysis reveals differentiated clinical and commercial dynamics across treatment type, route of administration, drug class, indication, and end user that inform tailored product and market strategies. Based on treatment type, patients requiring prevention versus active treatment fall into distinct care pathways: prophylaxis encompasses both medical prophylaxis for high-risk medical inpatients and surgical prophylaxis for perioperative management, while therapeutic use covers acute therapy for immediate clot dissolution and long-term therapy for secondary prevention and chronic risk management. Each of these pathways carries unique demands for onset of action, monitoring, and patient education.

Examining route of administration highlights the strategic partition between injectable and oral solutions. Injectable therapies, delivered intravenously or subcutaneously, remain essential in acute hospital settings, emergency care, and perioperative protocols where rapid effect and titratable dosing are necessary. Oral administration, available as capsules or tablets, dominates long-term outpatient management and favors agents with predictable pharmacokinetics and convenient dosing regimens that support adherence. The distinction between these routes shapes logistics, patient experience, and site-of-care economics.

Drug class segmentation underscores competitive and clinical nuances. Antiplatelet agents, direct oral anticoagulants, low molecular weight heparins, unfractionated heparins, and vitamin K antagonists each serve defined roles across indications. Direct oral anticoagulants further divide into direct thrombin inhibitors and factor Xa inhibitors, with factor Xa inhibitors including apixaban, betrixaban, edoxaban, and rivaroxaban as prominent examples. Low molecular weight heparins comprise agents such as dalteparin, enoxaparin, and tinzaparin. Vitamin K antagonists, led by warfarin, continue to occupy niches where cost, monitoring infrastructure, or specific contraindications to other agents make them appropriate. These differences influence formulary decisions, clinical guidelines, and patient counseling.

Indication segmentation-atrial fibrillation, deep vein thrombosis, and pulmonary embolism-drives product positioning and value communication, as therapeutic goals and acceptable risk profiles differ by condition. End user segmentation, consisting of hospitals and retail pharmacies, further delineates distribution models and contracting mechanisms: hospitals focus on acute care readiness and inventory management for injectable stock, whereas retail pharmacies prioritize adherence programs and outpatient access to oral agents. Understanding these layered segments enables manufacturers to refine messaging, optimize channel strategies, and tailor evidence generation to the specific needs of clinicians and payers.

How distinct regional clinical practices, reimbursement frameworks, and supply chain realities across the Americas, Europe Middle East & Africa, and Asia-Pacific determine differentiated commercialization approaches

Regional dynamics shape clinical practice, regulatory expectations, and commercial approaches across the three major global clusters of the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinical adoption trends emphasize broad acceptance of oral anticoagulants with growing focus on outpatient management infrastructure, while payers and integrated health systems press for robust real-world outcomes to support formulary placement. Market access discussions are frequently driven by total cost of care considerations and the impact of therapies on hospitalization rates and readmissions.

In Europe Middle East & Africa, heterogeneous regulatory pathways and variable healthcare financing models create a mosaic of adoption timelines. Many markets within this region prioritize comparative effectiveness and health technology assessment evidence, which elevates the importance of head-to-head outcomes and health economic modeling. Local clinical guidelines, reimbursement criteria, and procurement frameworks can vary substantially, encouraging manufacturers to pursue tailored market access strategies and region-specific evidence generation.

The Asia-Pacific region exhibits rapid uptake of novel agents in urban tertiary centers alongside persistent reliance on injectable therapies and vitamin K antagonists in lower-resource settings. Supply chain localization and pricing sensitivity are particularly salient here, influencing decisions on manufacturing partnerships and tiered pricing strategies. Across all regions, demographic shifts, aging populations, and rising prevalence of atrial fibrillation and venous thromboembolism reinforce the need for adaptable commercial playbooks that consider regional payer structures, patient affordability, and distribution complexity.

Competitive and strategic company behaviors that drive differentiation, portfolio defense, and strategic partnerships across the thrombosis therapeutics ecosystem

Competitive dynamics among established pharmaceutical companies, emerging specialty developers, and generic manufacturers shape innovation trajectories and market entry strategies in thrombosis therapeutics. Incumbent firms with broad cardiovascular portfolios leverage scale, established clinician relationships, and distribution networks to defend market positions and extend product lifecycles through label expansions, combination strategies, or enhanced patient support services. At the same time, nimble specialty companies focus on niche indications, novel mechanisms of action, and partnerships to accelerate clinical development and market penetration.

The generics and biosimilar segment exerts pressure on pricing and access, particularly for legacy agents such as warfarin and older heparin formulations. This environment incentivizes originator companies to differentiate through evidence generation, real-world safety data, and integrated services that address adherence and monitoring gaps. Strategic alliances between pharmaceutical companies and technology firms are increasingly common, aiming to pair pharmacotherapies with digital adherence platforms, remote monitoring, and clinical decision support tools to improve outcomes and demonstrate value to payers.

Mergers, acquisitions, and licensing deals continue to be tactical levers for portfolio diversification and geographic expansion. Firms that successfully combine clinical differentiation with scalable manufacturing and resilient supply chains gain competitive advantage in an environment where regulatory expectations and procurement practices are tightening. Moreover, investment in reversal agents, rapid diagnostics, and specialty formulations creates adjacent opportunities that can fortify a company's position across acute and chronic care settings.

Actionable strategic steps for manufacturers to fortify supply chains, demonstrate value through real-world evidence, and tailor commercialization for hospital and retail channels

Industry leaders can act now to protect and grow their positions by adopting a set of practical, evidence-based strategies that align clinical value with commercial execution. Prioritize investments in robust real-world evidence generation that addresses payer and clinician questions regarding comparative effectiveness, safety in special populations, and impacts on healthcare utilization. Pair these data initiatives with targeted medical affairs outreach to translate evidence into clinical practice and formulary acceptance.

Strengthen supply chain resilience through supplier diversification, investment in local or nearshore manufacturing capabilities for critical components, and development of contingency inventory strategies to mitigate tariff and trade disruptions. These operational steps will reduce vulnerability to cross-border cost pressures and ensure continuity for both oral and injectable portfolios. In parallel, design differentiated patient support programs that enhance adherence, offer education on bleeding risk management, and facilitate timely transitions of care between hospital and outpatient settings.

Adopt a channel-specific commercial approach that recognizes the distinct needs of hospitals and retail pharmacies, tailoring contracting, educational resources, and distribution models accordingly. Collaborate with payers to pilot outcomes-based agreements where appropriate, and explore value-added services such as digital adherence tools or bundled care pathways that demonstrate measurable improvements in outcomes. Finally, maintain a disciplined pipeline strategy that balances incremental innovation with disruptive research into novel mechanisms and reversal technologies, ensuring sustained clinical relevance and long-term growth potential.

An integrated research approach combining rigorous secondary evidence review, stakeholder interviews, and triangulated synthesis to validate clinical and commercial insights

The research approach underpinning this analysis combined comprehensive secondary review, expert consultation, and structured synthesis to ensure rigor and relevance. Secondary research included review of peer-reviewed clinical literature, regulatory guidance documents, public disclosures, and healthcare utilization studies to establish a baseline understanding of clinical practice patterns, therapeutic differentiation, and policy drivers. This material provided the factual foundation for evaluating how clinical and commercial variables interact across therapy classes and care settings.

Primary research comprised in-depth interviews with clinicians, hospital pharmacists, payer representatives, and industry executives to validate trends, explore decision drivers, and surface implementation barriers in real-world settings. Thematic analysis of these qualitative inputs helped prioritize the issues of greatest consequence to stakeholders. Findings were triangulated with proprietary databases of product approvals, pharmacovigilance summaries, and published health economic models to ensure consistency and to contextualize strategic implications.

Analytic limitations are acknowledged: regional heterogeneity can produce variability in adoption timelines and procurement practices, and rapidly evolving clinical data may shift practice patterns beyond the study window. To mitigate these limitations, the study emphasizes cross-validation, conservative interpretation of emerging data, and transparency in methodological assumptions. Readers seeking bespoke applications of the findings are encouraged to request targeted scenario analyses or supplementary data extracts tailored to specific geographies or product portfolios.

Concluding synthesis of how clinical evolution, supply chain adaptation, and evidence-driven commercial strategies converge to shape the future of thrombosis therapeutics

In summary, thrombosis therapeutics are navigating a period of meaningful and sustained change driven by clinical innovation, shifting care delivery models, and commercial pressures from policy and supply chain dynamics. The rise of oral anticoagulants and the continuing relevance of injectables in acute care require differentiated strategies that account for route-specific logistics, patient experience, and site-of-care economics. Supply chain resilience and evidence-based value demonstration are now central to securing market access and sustaining uptake across diverse healthcare systems.

Manufacturers that succeed will integrate robust real-world evidence, invest in targeted digital and patient support solutions, and align manufacturing strategies to mitigate trade-related risk. Regional nuance matters: tailored market access plans that address local reimbursement frameworks and clinical guideline expectations will outperform one-size-fits-all approaches. Competitive advantage will accrue to organizations that combine clinical differentiation with operational excellence and that proactively engage payers and providers to demonstrate measurable improvements in outcomes.

These conclusions underscore the imperative for timely action. By leveraging the strategic considerations and operational recommendations outlined in this analysis, stakeholders can enhance their readiness to respond to evolving clinician preferences, regulatory scrutiny, and procurement dynamics, thereby improving patient care and commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of direct oral anticoagulants over heparin in postoperative care
  • 5.2. Increasing investment in personalized thrombosis therapies driven by genetic biomarker profiling
  • 5.3. Emergence of long acting subcutaneous factor IX treatments reducing dosing frequency in hemophilia B patients
  • 5.4. Growing integration of digital health platforms for remote monitoring of anticoagulant therapy adherence
  • 5.5. Strategic partnerships between biotech startups and large pharma to accelerate novel antithrombotic drug development
  • 5.6. Rising demand for reversal agents in oral anticoagulation amid expanding DOAC patient population
  • 5.7. Regulatory approval pathways streamlined for biosimilar anticoagulants amid cost containment pressures
  • 5.8. Expansion of real world evidence studies to assess long term safety and efficacy of new thrombosis drugs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Thrombosis Drug Market, by Treatment Type

  • 8.1. Prophylaxis
    • 8.1.1. Medical Prophylaxis
    • 8.1.2. Surgical Prophylaxis
  • 8.2. Therapeutic
    • 8.2.1. Acute Therapy
    • 8.2.2. Long Term Therapy

9. Thrombosis Drug Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral
    • 9.2.1. Capsule
    • 9.2.2. Tablet

10. Thrombosis Drug Market, by Drug Class

  • 10.1. Antiplatelet Agents
  • 10.2. Direct Oral Anticoagulants
    • 10.2.1. Direct Thrombin Inhibitors
    • 10.2.2. Factor Xa Inhibitors
      • 10.2.2.1. Apixaban
      • 10.2.2.2. Betrixaban
      • 10.2.2.3. Edoxaban
      • 10.2.2.4. Rivaroxaban
  • 10.3. Low Molecular Weight Heparins
    • 10.3.1. Dalteparin
    • 10.3.2. Enoxaparin
    • 10.3.3. Tinzaparin
  • 10.4. Unfractionated Heparins
  • 10.5. Vitamin K Antagonists
    • 10.5.1. Warfarin

11. Thrombosis Drug Market, by Indication

  • 11.1. Atrial Fibrillation
  • 11.2. Deep Vein Thrombosis
  • 11.3. Pulmonary Embolism

12. Thrombosis Drug Market, by End User

  • 12.1. Hospital
  • 12.2. Retail Pharmacy

13. Thrombosis Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Thrombosis Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Thrombosis Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Bayer AG
    • 16.3.2. Bristol-Myers Squibb Company
    • 16.3.3. Pfizer Inc.
    • 16.3.4. Boehringer Ingelheim GmbH
    • 16.3.5. Daiichi Sankyo Company, Limited
    • 16.3.6. Leo Pharma A/S
    • 16.3.7. Johnson & Johnson
    • 16.3.8. Aspen Pharmacare Holdings Limited
    • 16.3.9. GlaxoSmithKline plc
    • 16.3.10. Amgen Inc.
    • 16.3.11. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. THROMBOSIS DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. THROMBOSIS DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. THROMBOSIS DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY MEDICAL PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY MEDICAL PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY MEDICAL PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY MEDICAL PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY MEDICAL PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY MEDICAL PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SURGICAL PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ACUTE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ACUTE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ACUTE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ACUTE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ACUTE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ACUTE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LONG TERM THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LONG TERM THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LONG TERM THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LONG TERM THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LONG TERM THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LONG TERM THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ANTIPLATELET AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY APIXABAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY APIXABAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY APIXABAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY APIXABAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY APIXABAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY APIXABAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY BETRIXABAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY BETRIXABAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY BETRIXABAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY BETRIXABAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY BETRIXABAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY BETRIXABAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY EDOXABAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY EDOXABAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY EDOXABAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY EDOXABAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY EDOXABAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY EDOXABAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RIVAROXABAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RIVAROXABAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RIVAROXABAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RIVAROXABAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RIVAROXABAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RIVAROXABAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DALTEPARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DALTEPARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DALTEPARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DALTEPARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DALTEPARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DALTEPARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ENOXAPARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ENOXAPARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ENOXAPARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ENOXAPARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ENOXAPARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ENOXAPARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TINZAPARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TINZAPARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TINZAPARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TINZAPARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TINZAPARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY TINZAPARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY UNFRACTIONATED HEPARINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY UNFRACTIONATED HEPARINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY UNFRACTIONATED HEPARINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY UNFRACTIONATED HEPARINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY UNFRACTIONATED HEPARINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY UNFRACTIONATED HEPARINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY WARFARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY WARFARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY WARFARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY WARFARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY WARFARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY WARFARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY VITAMIN K ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA THROMBOSIS DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY LOW MOLECULAR WEIGHT HEPARINS, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE,